Last reviewed · How we verify
LOXO-783
At a glance
| Generic name | LOXO-783 |
|---|---|
| Also known as | LY3849524 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- A Study of [14C]-LOXO-783 in Healthy Adult Participants (PHASE1)
- A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants (PHASE1)
- A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LOXO-783 CI brief — competitive landscape report
- LOXO-783 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI